Robert Figlin, MD of Samuel Oschin Comprehensive Cancer Institute explains the use of checkpoint inhibitors is changing the treatment standards for renal cell carcinoma. This was recorded at the 2017 Annual Meeting Annual Meeting in Chicago, IL.
How are checkpoint inhibitors changing the way RCC is treated?
